MedTrace Logo MedTrace
Clinical Trials News Drugs Diseases Companies About

Radiation Necrosis

  1. Home
  2. Diseases
  3. Radiation Necrosis
  4. Clinical Trials

Clinical Trials Related to Radiation Necrosis

Related studies linked through entity extraction aliases.

NCT07422168

Hyperbaric Oxygen Therapy for Treatment of Severe Radiation-Induced Complications

Status
COMPLETED
Phase
NA

NCT06888817

Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases

Status
RECRUITING
Phase
PHASE3

NCT05762172

Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis

Status
COMPLETED
Phase
NA

NCT05124912

REMASTer: REcurrent Brain Metastases After SRS Trial

Status
RECRUITING
Phase
NA

NCT02819479

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

Status
COMPLETED
Phase
PHASE2

NCT02212964

Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2*

Status
COMPLETED
Phase
N/A

NCT01651078

Laser Ablation After Stereotactic Radiosurgery

Status
COMPLETED
Phase
N/A

NCT01201850

The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors

Status
TERMINATED
Phase
NA

NCT00285324

Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis

Status
COMPLETED
Phase
N/A

Clinical Trials

Explore studies by the year of their last update.

  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005

News & Analysis

Latest news and insights on clinical trials and medical research.

Browse All News →
MedTrace Logo MedTrace
About Privacy Policy Terms of Service Medical Disclaimer

© 2026 MedTrace.
Open-access medical & pharmaceutical data intelligence.